Business Description
Phio Pharmaceuticals Corp
NAICS : 325412
SIC : 2834
ISIN : US71880W5013
Total Employee Number:
6Description
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.95 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 74.2 | |||||
3-Year EPS without NRI Growth Rate | 74.8 | |||||
3-Year FCF Growth Rate | 76.1 | |||||
3-Year Book Growth Rate | -72.7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.16 | |||||
9-Day RSI | 47.66 | |||||
14-Day RSI | 46.42 | |||||
3-1 Month Momentum % | -12.4 | |||||
6-1 Month Momentum % | -8.62 | |||||
12-1 Month Momentum % | -56.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 18.32 | |||||
Quick Ratio | 18.32 | |||||
Cash Ratio | 17.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -350.6 | |||||
Shareholder Yield % | -127.32 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -79.55 | |||||
ROA % | -72.74 | |||||
ROIC % | -12462.12 | |||||
3-Year ROIIC % | -249.11 | |||||
ROC (Joel Greenblatt) % | -130852.27 | |||||
ROCE % | -83.79 | |||||
Moat Score | 1 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.57 | |||||
PB Ratio | 0.72 | |||||
Price-to-Tangible-Book | 0.72 | |||||
EV-to-EBIT | 0.45 | |||||
EV-to-EBITDA | 0.45 | |||||
EV-to-Forward-Revenue | 0.05 | |||||
EV-to-FCF | 0.48 | |||||
| Price-to-Net-Current-Asset-Value | 0.72 | |||||
| Price-to-Net-Cash | 0.74 | |||||
Earnings Yield (Greenblatt) % | 222.22 | |||||
FCF Yield % | -90.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PHIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Phio Pharmaceuticals Corp Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.434 | ||
| Beta | 1.6261 | ||
| 3-Year Sharpe Ratio | -0.83 | ||
| 3-Year Sortino Ratio | -1.12 | ||
| Volatility % | 57.85 | ||
| 14-Day RSI | 46.42 | ||
| 14-Day ATR ($) | 0.054201 | ||
| 20-Day SMA ($) | 1.03049 | ||
| 12-1 Month Momentum % | -56.65 | ||
| 52-Week Range ($) | 0.8127 - 4.1899 | ||
| Shares Outstanding (Mil) | 11.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Phio Pharmaceuticals Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Phio Pharmaceuticals Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 125 days | ||
| General meeting for 2026 | 2026-09-11 09:00 | In 63 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 34 days | ||
| Life Sciences Virtual Investor Forum | 2026-06-25 15:00 | 1.02 (-1.92%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 1.15 (+0.00%) | ||
| Annual report for 2025 | 2026-03-05 | 1.15 (+9.52%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 1.15 (+9.52%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 1.58 (-1.25%) | ||
| General meeting for 2025 | 2025-09-11 09:00 | 2.47 (-3.89%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 2.19 (+4.29%) |
Show
Entries
Phio Pharmaceuticals Corp Frequently Asked Questions
What is Phio Pharmaceuticals Corp(PHIO)'s stock price today?
The current price of PHIO is $1.02. The 52 week high of PHIO is $4.19 and 52 week low is $0.81.
When is next earnings date of Phio Pharmaceuticals Corp(PHIO)?
The next earnings date of Phio Pharmaceuticals Corp(PHIO) is 2026-08-14 Est..
Does Phio Pharmaceuticals Corp(PHIO) pay dividends? If so, how much?
Phio Pharmaceuticals Corp(PHIO) does not pay dividend.
Guru Commentaries on NAS:PHIO
No articles.
Press Release
Articles on Phio Pharmaceuticals Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers